Switch theme
Sign up to access all valuation multiples
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
1996
21
LTM Revenue $38.9M
LTM EBITDA $1.7M
$1.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Labo Euromed has a last 12-month revenue of $38.9M and a last 12-month EBITDA of $1.7M.
In the most recent fiscal year, Labo Euromed achieved revenue of $58.2M and an EBITDA of -$4.7M.
Labo Euromed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Labo Euromed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $120M | $58.2M | XXX | XXX | XXX |
| Gross Profit | n/a | $36.0M | XXX | XXX | XXX |
| Gross Margin | NaN% | 62% | XXX | XXX | XXX |
| EBITDA | $9.2M | -$4.7M | XXX | XXX | XXX |
| EBITDA Margin | 8% | -8% | XXX | XXX | XXX |
| Net Profit | n/a | $2.4M | XXX | XXX | XXX |
| Net Margin | NaN% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Labo Euromed's stock price is EUR 4 (or $4).
Labo Euromed has current market cap of EUR 10.2M (or $10.9M), and EV of EUR 1.4M (or $1.5M).
See Labo Euromed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5M | $10.9M | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Labo Euromed has market cap of $10.9M and EV of $1.5M.
Labo Euromed's trades at 0.0x LTM EV/Revenue multiple, and 0.8x LTM EBITDA.
Analysts estimate Labo Euromed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Labo Euromed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5M | XXX | XXX | XXX |
| EV/Revenue | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | XXX | XXX |
| P/E | -1.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLabo Euromed's NTM/LTM revenue growth is 5%
Labo Euromed's revenue per employee for the last fiscal year averaged $2.8M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Labo Euromed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Labo Euromed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Labo Euromed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -52% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -151% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -3% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ghitha Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Acomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Sligro Food Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Metcash | XXX | XXX | XXX | XXX | XXX | XXX |
| Reece | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Labo Euromed acquired XXX companies to date.
Last acquisition by Labo Euromed was XXXXXXXX, XXXXX XXXXX XXXXXX . Labo Euromed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Labo Euromed founded? | Labo Euromed was founded in 1996. |
| Where is Labo Euromed headquartered? | Labo Euromed is headquartered in France. |
| How many employees does Labo Euromed have? | As of today, Labo Euromed has 21 employees. |
| Is Labo Euromed publicy listed? | Yes, Labo Euromed is a public company listed on PAR. |
| What is the stock symbol of Labo Euromed? | Labo Euromed trades under ALEMG ticker. |
| When did Labo Euromed go public? | Labo Euromed went public in 2000. |
| Who are competitors of Labo Euromed? | Similar companies to Labo Euromed include e.g. Ghitha Holding, Acomo, Sligro Food Group, Metcash. |
| What is the current market cap of Labo Euromed? | Labo Euromed's current market cap is $10.9M |
| What is the current revenue of Labo Euromed? | Labo Euromed's last 12-month revenue is $38.9M. |
| What is the current EBITDA of Labo Euromed? | Labo Euromed's last 12-month EBITDA is $1.7M. |
| What is the current EV/Revenue multiple of Labo Euromed? | Current revenue multiple of Labo Euromed is 0.0x. |
| What is the current EV/EBITDA multiple of Labo Euromed? | Current EBITDA multiple of Labo Euromed is 0.8x. |
| What is the current revenue growth of Labo Euromed? | Labo Euromed revenue growth between 2023 and 2024 was -52%. |
| Is Labo Euromed profitable? | Yes, Labo Euromed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
